Medical Economics Expert Panel 12.2
News|Videos|February 12, 2025

Drug prices: Medicare coverage of antiobesity medications

A discussion about the Medicare Drug Price Negotiation Program with Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research.

Weight loss and antiobesity are not the same thing, said Adina Lasser, director of public policy and government affairs with the Alliance for Aging Research (AAR). Based on scientific and medical evidence, AAR publicly has stated its support for Medicare coverage of the GLP-1 RA antiobesity drugs that have become blockbusters across health care. Here she explains the organization’s stance ono those medications. AAR also commissioned a white paper titled “CMS Has the Legal Authority to Cover Anti-Obesity Medications (and Should).” It was prepared by Akin Gump Strauss Hauer & Field LLP and published in 2024. Federal rules have long prohibited Medicare from covering drugs or classes of drugs when used for “anorexia, weight loss, or weight gain.” But AAR argues that statutory restriction does not prohibit coverage of the antiobesity drugs, according to the paper.


Related to this article

Vincent Cantone: ©WellSpan Health
With projected shortfalls of 86,000 to more than 187,000 physicians within a decade, burnout, an aging workforce and capped residency slots are squeezing supply. Here are the training, payment, prior authorization and workplace changes that could help close the gap.
Qasim Faizan: ©WeBill Health
Starting Jan. 1, Medicare will pay 20% less for the lower-valued service when an office visit billed with modifier 25 falls on the same day as a zero-day global procedure. One claims report priced at local 2027 rates shows independent practices their exposure, and three documentation habits protect the visits that still qualify for full payment.